Bristol Myers Squibb (BMS) has signed a strategic agreement with Anthropic to implement its Claude platform across its global operations.

The new healthcare firm will operate across the North American, APAC and European markets, which make up around 90% of the global R&D spend.

As China continues to inch ahead of competition in terms of trial initiations, immunology and metabolic disease trials attract sponsor eyes.

QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery.

SERB Pharmaceuticals has signed an agreement to acquire exclusive development and commercialisation rights to Idefirix from Hansa Biopharma for a total of $133.6m.

The UK has received doses of antiviral medicine favipiravir as a precaution in case hantavirus spreads in the country. The medicine, developed by Fujifilm subsidiary Toyama Chemical in Japan, has been ...

Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.

ITALVACUUM will participate in EXPOQUIMIA 2026, taking place in Barcelona from 2 to 5 June, where the company will present its vacuum drying technologies developed for pharmaceutical and ...

The WHO has classed this outbreak as “extraordinary” due to the lack of therapeutic options and epidemiological trends.

Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.

The wider US HHS is going through a leadership upheaval, as Republicans aim to keep voters on side amid the looming midterm elections.

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.